INM: InMed Pharmaceuticals Inc. Stock

by  •  • Comments Off on INM: InMed Pharmaceuticals Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3.25
Enterprise Value ($M) -2.33
Book Value ($M) 8.40
Book Value / Share 11.69
Price / Book 0.39
NCAV ($M) 5.21
NCAV / Share 7.26
Price / NCAV 0.62

Profitability (mra)
Return on Invested Capital (ROIC) -0.72
Return on Assets (ROA) -0.62
Return on Equity (ROE) -0.71

Liquidity (mrq)
Quick Ratio 4.22
Current Ratio 5.07

Balance Sheet (mrq) ($M)
Current Assets 7.28
Assets 10.47
Liabilities 2.07
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 4.60
Operating Income -8.13
Net Income -7.68

Cash Flow Statement (mra) ($M)
Cash From Operations -6.99
Cash from Investing -0.01
Cash from Financing 4.65

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Armistice Capital, Llc 4.99 14.86
11-12 13G AdvisorShares Trust 8.77
01-04 13G Sabby Management, Llc 9.99

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-09-30 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT T
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-02-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT
2023-12-21 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 ☐ TRANSITI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-27 5,700 19,288 29.55
2024-11-26 1,964 21,521 9.13
2024-11-25 4,229 25,698 16.46
2024-11-22 7,031 31,660 22.21

(click for more detail)

Similar Companies
IMTX – Immatics N.V. INDP – Indaptus Therapeutics, Inc.
INKT – MiNK Therapeutics, Inc. INMB – INmune Bio, Inc.
INTS – Intensity Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io